Literature DB >> 3492611

Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III.

L E Henderson, R Sowder, T D Copeland, S Oroszlan, L O Arthur, W G Robey, P J Fischinger.   

Abstract

Class II histocompatibility DR antigen alpha and beta chains were isolated from preparations of human T-cell lymphotropic virus type III grown in human H-9 cells. The proteins were purified by reversed-phase high-pressure liquid chromatography and identified by direct N-terminal amino acid sequence analysis of each chain. The purified DR alpha chain had an N-terminal amino acid sequence identical to the known sequence of human DR alpha chain through the first 37 residues. The N-terminal amino acid sequence of the purified DR beta chain was identical to that of human DR4 beta chain. The DR alpha and beta chains appeared to be identical to the p34-36K and p30-32K proteins, respectively, concentrated in immunostimulatory complexes prepared from unfractionated virus and were the major immunogens in these complexes. These proteins represent a ready source of antigens which can cause false-positive enzyme-linked immunosorbent assay reactions in individuals previously exposed to allogenic histocompatibility antigens. The removal of the DR chains from virus preparations by use of available monoclonal antibodies or other means should result in a lower rate of initial false-positive enzyme-linked immunosorbent assay reactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492611      PMCID: PMC253995          DOI: 10.1128/JVI.61.2.629-632.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  HLA antibodies detected by ELISA HTLV-III antibody kits.

Authors:  J B Hunter; J E Menitove
Journal:  Lancet       Date:  1985-08-17       Impact factor: 79.321

2.  HLA DR4 antibodies cause positive HTLV-III antibody ELISA results.

Authors:  P Kühnl; S Seidl; G Holzberger
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

3.  Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications.

Authors:  S H Weiss; J J Goedert; M G Sarngadharan; A J Bodner; R C Gallo; W A Blattner
Journal:  JAMA       Date:  1985-01-11       Impact factor: 56.272

4.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

5.  Clinical findings and serological evidence of HTLV-III infection in homosexual contacts of patients with AIDS and persistent generalised lymphadenopathy in London.

Authors:  B G Gazzard; D C Shanson; C Farthing; A G Lawrence; R S Tedder; R Cheingsong-Popov; A Dalgleish; R A Weiss
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

6.  Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs.

Authors:  L W Kitchen; F Barin; J L Sullivan; M F McLane; D B Brettler; P H Levine; M Essex
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

7.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  Purification and N-terminal amino acid sequence comparisons of structural proteins from retrovirus-D/Washington and Mason-Pfizer monkey virus.

Authors:  L E Henderson; R Sowder; G Smythers; R E Benveniste; S Oroszlan
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products.

Authors:  L E Henderson; R Sowder; T D Copeland; G Smythers; S Oroszlan
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

10.  Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS.

Authors:  V S Kalyanaraman; C D Cabradilla; J P Getchell; R Narayanan; E H Braff; J C Chermann; F Barré-Sinoussi; L Montagnier; T J Spira; J Kaplan
Journal:  Science       Date:  1984-07-20       Impact factor: 47.728

View more
  28 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Roles for endocytosis in lentiviral replication.

Authors:  M Marsh; A Pelchen-Matthews; J A Hoxie
Journal:  Trends Cell Biol       Date:  1997-01       Impact factor: 20.808

Review 3.  Virus maturation by budding.

Authors:  H Garoff; R Hewson; D J Opstelten
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

4.  Concomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.

Authors:  K S Chang; L C Wang; C L Gao; S Alexander; R C Ting; A Bodner; T Log; A F Kuo; P Strickland
Journal:  Eur J Epidemiol       Date:  1988-12       Impact factor: 8.082

5.  The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Authors:  R Cantin; J F Fortin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques.

Authors:  Y Wang; L Tao; E Mitchell; W M Bogers; C Doyle; C A Bravery; L A Bergmeier; C G Kelly; J L Heeney; T Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 7.  Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

8.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

Review 10.  Morphogenesis and morphology of HIV. Structure-function relations.

Authors:  H R Gelderblom; M Ozel; G Pauli
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.